Member Info for Walkley

I cannot believe that Institution Investors worry about whether their holding worth �3m (as an example) is held as 1 million shares of �3 each or 10 million shares of 30p each. The market capitalisation is exactly the same. That some private investors may be influenced is possible (I have resisted inserting a derogatory adjective in front of private).

2.7p being paid. Surely some news imminent.

Does anyone know what is going on? Looks as if some one is stirring the pot.

Shorting: selling shares that you don't own in the hope that you can buy them later for less than you sold them for. Useful if you expect the price to drop.

From that Tweet: "A utrophin based strategy is a highly promising approach applicable to all DMD patients irrespective of their genetic defect. Whereas accurate utrophin and regeneration quantification tools are urgently needed, the foundation of utrophin based therapies, defined 20 years ago, recently delivered first promising results in DMD patients with ezutromid. The field is at an exciting stage on the road of a universal treatment for all DMD patients."

IDOX has successfully established itself as the supplier of software for UK local government systems. some of this, particularly the election software is usable in other countries. The recent "eye off the ball" problems has made the company much more affordable to one of the major software houses who would like to add the capabilities that IDOX has to their portfolios. Could the recent price improvement be a recognition that they may be using their slide rules to evaluate IDOX

Always good news when they spend real money! With costs cut, new contracts being signed monthly and some hopefully hungry and focused new direction at the top perhaps share price should head back up soon.

Dell 77, Sarepta seems to have no problem raising cash. In last five years they have raised $1,100m by issuing shares, (including $369m in 2017 and $385 m in 2016). if they felt that Ezutromid was vital to their DMD programme it is probable that they would be able to raise sufficient to pay cash to Summit plus an on-going royalty.

Tricky things these pharmaceuticals: ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that, in response to institutional demand, it has completed a fundraise totalling �10 million (before expenses) via a placing of 6,944,445 new ordinary shares of 10p each in the Company ("Ordinary Shares") at a price of 144p per share (the "Placing Shares") with new and existing investors (the "Placing"). Today's price 39p after phase 3 results not god enough

All very, very positive: Mr Glyn Edwards, Chief Executive Officer of Summit, commented: "This was a landmark year for Summit's Duchenne muscular dystrophy programme where we saw a statistically significant reduction in muscle damage and inflammation in patients after just 24-weeks of ezutromid treatment. This provides evidence that ezutromid is reducing the severity of the disease for these patients. "Strongly encouraged by these findings, we are accelerating preparatory activities for a placebo controlled trial of ezutromid and also preparing for a potential regulatory filing of ezutromid based on top-line data from the full 48-week results, which are expected in the third quarter of 2018. "Our infectious disease business has also made major strides over the past year. With funding support from BARDA, we are preparing to initiate our Phase 3 trials for ridinilazole, a precision antibiotic for the treatment of C. difficile infections. Based on the discovery and development platform we acquired in 2017, we are also building a pipeline of new mechanism antibiotics as we position ourselves as leaders in the field of antibacterials. "With two lead clinical programmes in DMD and CDI, and a growing pipeline of early-stage compounds, we are building a fully-integrated company focused on advancing novel mechanism drugs as new standards of care."

"Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on 10 April 2018 at 3:00pm CEST in Monte Carlo, Monaco." ...and people ask why it costs so much to develop new drugs!!

It is unlikely that Summit will take all those shots at goal themselves. Surely they will pass some of the balls on to other players - perhaps those with deeper pockets . Whilst no a football fan I believe that it is known as an "assist" and can help your score in fantasy football! Seriously though if Summit can produce a number of drug candidates then we have a business worth more than �125m

No mention of F. Hoffmann - La Roche Limited ('Roche'), - Roche is obligated to pay specified development, commercialisation and sales milestone payments related to any compound developed under the platform that is or has been optioned by Roche. Can we assume that they do not have an option on this antibiotic candidate?

More good news.

Excellent news - given the benefit that may result from Utrophin Modulation to a much wider group of sufferers than Sarepta's treatment this could cause some rerating of Summit soon.

And results are out!! With no new serious issues. Cash generated by operations �15.165m (last year �13.548m) in my opinion IDOX still a good operation

From the last RNS: "As a result of the matters above, the Board expects that the Company's final results for the 2017 financial year will be announced in February 2018." 7 hours to go!

28.8p trades are buys!

Hopefully first of many! "Intercede, the software and service company specialising in identity, credential management and secure mobility, announces that a Middle Eastern country has selected Intercede's MyID solution to power the issuance of mobile government identities to its citizens. Under this program, any citizen with an existing national identity card will be able to easily and securely generate a new government digital identity on their smart phone via a government app. Using Intercede MyID software, this digital identity can then be used for accessing a mobile eco-system of government services, health care, banking and e-commerce. This will significantly increase the efficiency and security of public service delivery and return enhanced privacy and convenience to citizens and consumers." see RNS for more details

Its my birthday - This year Nando's (a first - never been before). Next year Le Manoir?